The lack of efficacy of another anti-TNF-α drug, the soluble receptor Etanercept, was proven in a randomized controlled trial conducted on adults with moderate-to-severe asthma already taking high doses of ICS; the trial proved no difference compared to the placebo over 12 weeks of administration [12]. This evidence concerns the gene TNF and asthma.